Inés Fallon: Delighted to announce our significant contribution to pediatric oncology research!
Inés Fallon, Drug Discovery Scientist at Oncoheroes Biosciences, shared a post by Oncoheroes Biosciences on LinkedIn, adding the following:
“Delighted to announce our significant contribution to pediatric oncology research! Our peer-reviewed paper, featured in the esteemed SLAS Discovery Journal, underscores our dedication to revolutionizing treatments for medulloblastoma.
If you are interested in learning more, feel free to take a look.”
Quoting Oncoheroes Biosciences’s post:
“Breaking news!
We’re excited to share that Oncoheroes Biosciences has achieved a significant milestone in pediatric oncology research, by engineering a screening platform designed to minimize toxicity risks and advance molecules with the highest likelihood of efficacy and safety for patients.
Cesare Spadoni, Oncoheroes’ Chief Operating Officer and co-founder elaborates, ‘The development of this platform is step forward in our quest to accelerate pediatric oncology drug development. By prioritizing safety and efficacy, we aim to accelerate the translation of scientific discoveries into life-saving therapies.’
Our paper, published in SLAS (Society for Laboratory Automation and Screening) journal, highlights our commitment to advancing treatments for medulloblastoma. Explore the impact of our work and join us in making a difference for young patients.”
Read further.
Source: Inés Fallon/LinkedIn and Oncoheroes Biosciences/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023